Patient Leaflet Updated 10-Jul-2026 | Vifor Fresenius Medical Care Renal Pharma UK Ltd
Avacopan Vifor 10 mg hard capsules
Avacopan Vifor 10 mg hard capsules
avacopan
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
1. What Avacopan Vifor is and what it is used for
2. What you need to know before you take Avacopan Vifor
3. How to take Avacopan Vifor
4. Possible side effects
5. How to store Avacopan Vifor
6. Contents of the pack and other information
Avacopan Vifor contains the active substance avacopan, which attaches to a specific protein in the body, called complement 5a receptor.
Avacopan Vifor is used to treat adults with a gradually worsening disease caused by inflammation of the small blood vessels, called granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA):
Complement 5a receptor has a key role in stimulating inflammation. This medicine attaches to it and prevents it from working, thereby reducing inflammation of blood vessels seen in these diseases.
Avacopan Vifor can be used together with other treatments prescribed by your doctor.
Talk to your doctor before taking Avacopan Vifor and during treatment if you had or have:
Avacopan Vifor is not recommended in patients with
Your doctor will carry out blood tests before and regularly during treatment, to check:
Your doctor will decide to temporarily stop or permanently discontinue treatment.
Your doctor will also monitor you for signs and symptoms of an infection called Neisseria meningitidis. This is recommended for adult patients with GPA or MPA.
It is recommended that you have treatment to prevent the lung infection Pneumocystis jirovecii pneumonia during treatment with Avacopan Vifor.
It is recommended to give vaccinations before treatment with Avacopan Vifor or when there is no active disease (granulomatosis with polyangiitis or microscopic polyangiitis).
Severe and often painful swelling under the skin, mainly in the face, has been reported during treatment with Avacopan Vifor. If this affects the throat it can make it hard to breathe. Stop treatment and seek urgent medical advice if swelling of the face, lips, tongue or throat, or breathing difficulties occur.
Do not give this medicine to children under 18 years as there is not enough evidence to know if this medicine is safe and effective in this age group.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
It is important to tell your doctor especially if you use any of the following medicines:
If short-term use of one of these medicines cannot be avoided during treatment with Avacopan Vifor, your doctor may regularly check your condition to see how well Avacopan Vifor is working.
Avacopan Vifor can affect or be affected by the following medicines.
Avoid grapefruit and grapefruit juice during treatment with Avacopan Vifor, as these can influence the effect of the medicine.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
It is considered unlikely that Avacopan Vifor will affect your ability to drive or to use machines.
This may cause stomach upset and diarrhoea.
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
The recommended dose is 3 capsules in the morning and 3 capsules in the evening.
Swallow the capsules whole with one glass of water. Do not crush, chew or open the capsules. Take the capsules with a meal, 3 capsules in the morning and 3 capsules in the evening.
Talk to your doctor immediately.
If you have more than 3 hours to go until your next scheduled dose, take the missed dose as soon as possible and then take your next dose at the right time.
If it is less than 3 hours to your next dose, do not take the missed dose. Just take your next dose at the usual time.
Do not take a double dose to make up for a forgotten dose.
Stop treatment and seek urgent medical advice if swelling of the face, lips, tongue or throat, or breathing difficulties occur. In any other situations, do not stop taking this medicine without talking to your doctor.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Not known (frequency cannot be estimated from the available data)
Very common
Common
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and bottle after “EXP”. The expiry date refers to the last day of that month.
This medicine does not require any special temperature storage conditions. Store in the original bottle in order to protect from light.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Avacopan Vifor 10 mg hard capsules are made of a yellow body and light orange cap with “CCX168” in black ink.
Capsules are 22 mm long, with a diameter of 8 mm.
The capsules are packed in plastic bottles with a child-resistant closure.
Avacopan Vifor 10 mg hard capsules are available in packs containing 30 or 180 hard capsules.
Not all pack sizes may be marketed.
For any information about this medicine, please contact the Marketing Authorisation Holder.
This leaflet was last revised in June 2026.
Other sources of information
Detailed information on this medicine is also available on the following URL: http://www.tavneos-patient.eu.
Point, 29 Market Street, Maidenhead, SL6 8AA, UK
+44 (0)1276 452 341
+44 (0)1276 853 600
+44 (0)1276 853 633